Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Moderna, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention mFLUSIVA (mRNA-1010), all published on August 6, 2026.
Last mentioned: Aug 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Moderna, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention mFLUSIVA (mRNA-1010), all published on August 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mFLUSIVA (mRNA-1010). Shared-story counts are live from our verified record — not editorial picks.
The FDA has approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine, for all adults 50 and older. The decision, based on a Phase 3 study enrolling 40,805 participants, introduces a new tool for a demographic disproportionately affected by severe influenza. Healthcare providers and public health agencies now have a potentially more adaptable option that could reshape seasonal vaccination campaigns.
mFLUSIVA (mRNA-1010) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
